Dexmedetomidine
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mechanically-ventilated Neonates With Single-organ Respiratory Failure
Conditions
Mechanically-ventilated Neonates With Single-organ Respiratory Failure
Trial Timeline
Jul 28, 2011 → Apr 10, 2018
NCT ID
NCT01266252About Dexmedetomidine
Dexmedetomidine is a phase 3 stage product being developed by Orion Corporation for Mechanically-ventilated Neonates With Single-organ Respiratory Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT01266252. Target conditions include Mechanically-ventilated Neonates With Single-organ Respiratory Failure.
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03813277 | Approved | Completed |
| NCT02252523 | Phase 2 | UNKNOWN |
| NCT01266252 | Phase 3 | Completed |
| NCT00747721 | Phase 1 | Completed |
| NCT00226785 | Phase 3 | Terminated |